IP
ABCL icon

Intellectus Partners’s AbCellera Biologics ABCL Stock Holding History

Intellectus Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-385,000
Closed -$39.3K – 254
2022
Q4 		$39.3K Buy
+385,000
New +$4.45M 0.01% 253
2022
Q3 		– Sell
-10,000
Closed -$6K – 263
2022
Q2 		$6K Buy
+10,000
New +$84.7K ﹤0.01% 251
2021
Q3 		– Sell
-70,100
Closed -$158K – 276
2021
Q2 		$158K Buy
+70,100
New +$1.93M 0.04% 261

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Intellectus Partners's ABCL Position: Q1 2026 in Review

Intellectus Partners increased its AbCellera Biologics (ABCL) stake by 4.3% in Q1 2026, buying an estimated $81.7K and bringing the position to 546,083 shares worth $1.91M. The position accounts for 0.39% of the portfolio, ranked #69.

Intellectus Partners first reported a position in ABCL in Q2 2021 and has held it in 20 quarters since. The position peaked at $26.6M in Q2 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Intellectus Partners held 546,083 shares of AbCellera Biologics worth $1.91M as of Q1 2026.
  • Intellectus Partners bought 22,700 AbCellera Biologics shares in Q1 2026, an estimated $81.7K.
  • AbCellera Biologics made up 0.39% of Intellectus Partners's portfolio in Q1 2026, its #69 holding.
  • Intellectus Partners first reported a position in AbCellera Biologics in Q2 2021 and has held it in 20 quarters since.
  • Intellectus Partners's AbCellera Biologics position peaked at $26.6M in Q2 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Intellectus Partners's 13F filing for Q1 2026, filed 10 Apr 2026.